Ab-chminaca

Product Code: Ab-chminaca
Availability: In Stock
5.00€

Available Options

AB CHMINACA is an indazole-based manufactured cannabinoid. It is a powerful agonist of the CB1 receptor (Ki = 0.78 nM) and CB2 receptor (Ki = 0.45 nM) and completely substitutes for Δ9-THC in rodent separation thinks about, while being 16x more strong. Proceeding with the pattern seen in different cannabinoids of this age, it contains a valine amino corrosive amide buildup as a component of its structure, where more seasoned cannabinoids contained a naphthyl or adamantane deposit. 

AB CHMINACA is a logical reference standard arranged as an engineered cannabinoid. This item is expected for investigate and legal applications. 

AB CHMINACA, or N-[(2S)- 1-Amino-3-methyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)indazole-3-carboxamide, is a manufactured indazole cannabinoid tranquilize as it contains a substituted indazole center. A cyclohexylmethyl gather is bound to this indazole center at R1 of the indazole. This indazole is substituted at R3 with a carboxamide gathering. The terminal amine of this carboxamide is clung to a substituted propyl chain with an aminocarbonyl aggregate at R1 and a methyl amass at R2. 

Abdominal muscle CHMINACA (N-[(2S)- 1-Amino-3-methyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)indazole-3-carboxamide) is a medication that goes about as an intense agonist for the cannabinoid receptors which produces subjective impacts to some degree. It was created by Pfizer and unveiled in a 2009 patent as a potential pain relieving drug, yet was never sought after for human utilize.


This product is intended for research and forensic applications. Warning - this product is not for human or veterinary use.

Formal Name
N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide
CAS Number
1185887-21-1
Molecular Formula
C20H28N4O2
Formula Weight
356.5
Purity
≥98%
Formulation
A crystalline solid
λmax
210, 303 nm
SMILES
O=C(N[[email protected]](C(N)=O)C(C)C)C1=NN(CC2CCCCC2)C3=C1C=CC=C3
InChI Code
InChI=1S/C20H28N4O2/c1-13(2)17(19(21)25)22-20(26)18-15-10-6-7-11-16(15)24(23-18)12-14-8-4-3-5-9-14/h6-7,10-11,13-14,17H,3-5,8-9,12H2,1-2H3,(H2,21,25)(H,22,26)/t17-/m0/s1
InChI Key
KJNZIEGLNLCWTQ-KRWDZBQOSA-N
Warning - this product is not for human or veterinary use.

AB-Chminaca research chemical

Abdominal muscle CHMINACA (Item No. 15434) is a systematic reference standard sorted as an engineered cannabinoid.1 It has been found in Spice-type home grown mixes and is related with slurred discourse, disarray, torpidity, and absence of coordination in instances of driving under the influence.2 AB-CHMINACA is managed as a Schedule I compound in the United States. This item is proposed for look into and measurable applications.

Diversion of synthetic cannabinoids for abuse began in the early 2000s. Regardless of enactment restricting mixes at present on the medication showcase, unlawful producers keep on releasing new mixes for recreational utilize. This investigation analyzed new engineered cannabinoids, AB-CHMINACA (N-[1-amino-3-methyl-oxobutan-2-yl]-1-[cyclohexylmethyl]-1H-indazole-3-carboxamide), AB-PINACA [N-(1-amino-3-methyl-1-oxobutan-2-yl)- 1-pentyl-1H-indazole-3-carboxamide], and FUBIMINA [(1-(5-fluoropentyl)- 1H-benzo[d]imadazol-2-yl)(naphthalen-1-yl)methanone], with the theory that these mixes, similar to those before them, would be exceptionally helpless to manhandle. Cannabinoids were inspected in vitro for official and enactment of CB1 receptors, and in vivo for pharmacological impacts in mice and in Δ9-tetrahydrocannabinol (Δ9-THC) segregation. Abdominal muscle CHMINACA, AB-PINACA, and FUBIMINA bound to and initiated CB1 and CB2 receptors, and created locomotor concealment, antinociception, hypothermia, and catalepsy. Besides, these mixes, alongside JWH-018 [1-pentyl-3-(1-naphthoyl)indole], CP47,497 [rel-5-(1,1-dimethylheptyl)- 2-[(1R,3S)- 3-hydroxycyclohexyl]-phenol], and WIN55,212-2 ([(3R)- 2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenyl-methanone, monomethanesulfonate), substituted for Δ9-THC in Δ9-THC segregation. Rank request of intensity related with CB1 receptor-restricting proclivity, and each of the three mixes were full agonists in [35S]GTPγS authoritative, as contrasted and the fractional agonist Δ9-THC. Without a doubt, AB-CHMINACA and AB-PINACA showed higher adequacy than most known full agonists of the CB1 receptor. Primer investigation of urinary metabolites of the mixes uncovered the normal hydroxylation. Abdominal muscle PINACA and AB-CHMINACA are of potential enthusiasm as research apparatuses because of their exceptional compound structures and high CB1 receptor efficacies. Additionally thinks about on these synthetic substances are probably going to incorporate research on understanding cannabinoid receptors and different parts of the endocannabinoid framework that underlie the mishandle of engineered cannabinoids.

Synthesis of phytocannabinoid analogs was followed by development of bicyclic cannabinoids (e.g., CP55,940 [(−)-cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol]) and aminoalkylindoles [e.g., WIN55,212-2 ([(3R)-2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenyl-methanone, monomethanesulfonate)]. The effort was renewed with the discovery and initial characterization of the endocannabinoid system (Devane et al., 1988), which added the structural templates of arachidonic acid derivative agonists (anandamide and 2-arachidonoylglycerol) (Devane et al., 1992; Hanus et al., 2001) and a pyrazole antagonist, rimonabant (Rinaldi-Carmona et al., 1994). Structure-activity relationship studies focused on delineation of the ways in which these diverse chemical structures could bind to the two identified cannabinoid receptors (CB1 and CB2) and differentiation of features that might enhance selectivity for the CB2 cannabinoid receptor. CB1 receptor mediation of the marijuana-like psychoactive effects of cannabinoids was confirmed during this time (Wiley et al., 1995b), and the high correlation between binding affinity and potency for producing these psychoactive effects in mice was noted (Compton et al., 1993). The systematic synthesis of cannabinoids for use as research tools to probe the structure and functioning of the cannabinoid receptors or for use as lead candidates in medication development efforts continued to produce a multitude of novel synthetic cannabinoids (e.g., see Manera et al., 2008). After the initial publication of this medicinal chemistry research, much of it lay dormant, with the exception of occasional retrieval by scientists.


Abbreviations


AB-CHMINACA

N-[1-amino-3-methyl-oxobutan-2-yl]-1-[cyclohexylmethyl]-1H-indazole-3-carboxamide

AB-PINACA

N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide

AM-2201

[1-​(5-​fluoropentyl)-​1H-​indol-​3-​yl]-​1-​naphthalenyl-​methanone

ANOVA

analysis of variance

BSA

bovine serum albumin

CI

confidence interval

CP47,497

rel-5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol

CP55,940

(−)-cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol

FR10

fixed ratio 10

FUBIMINA

(1-(5-fluoropentyl)-1H-benzo[d]imadazol-2-yl)(naphthalen-1-yl)methanone

hCB

human CB

JWH-018

1-pentyl-3-(1-naphthoyl)indole

Δ9-THC

Δ9-tetrahydrocannabinol

UR-144

(1-​pentyl-​1H-​indol-​3-​yl)(2,​2,​3,​3-​tetramethylcyclopropyl)-​methanone

WIN55,212-2

[(3R)-2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenyl-methanone, monomethanesulfonate

XLR-11

(1-​(5-​fluoropentyl)-​1H-​indol-​3-​yl)(2,​2,​3,​3-​tetramethylcyclopropyl)methanone




Write a review

Please login or register to review